Key Highlights
- CSL (ASX:CSL) fell 1.75% over five days to 20 November, compared with a 5.18% decline in the S&P/ASX 200.
- CSL recorded a statutory net loss after tax of USD 2.6 billion and Underlying Profit before Amortisation of USD 3.1 billion.
- Pre-tax asset impairments totalled USD 7.1 billion in FY26, including USD 5.5 billion in the second half.
- At FY26 exchange rates the company expected FY27 Revenue to be in line with FY26 and underlying net profit to rise approximately 5%.
CSL (ASX:CSL) fell 1.75% to AUD 197.29 over the five days ending on 20 November 2026, with the S&P/ASX 200 down 5.18% for the same period. The biotechnology company’s FY26 disclosure detailed asset write-downs, changes in plasma product sales and separate revenue expectations for its three businesses.
CSL’s decline was smaller than the broad market’s
The S&P/ASX 200 dropped 469.70 points to 8,592.60 over the five days, a decline of 5.18%. CSL fell 3.43 percentage points less than the index on the same five-day measure. The AUD 3.52 move in CSL took the price from an implied starting level of AUD 200.81 to AUD 197.29.
In the same five-day window, Sigma rose 0.35%, Aristocrat fell 2.03% and QBE fell 2.50%. The five-day returns for CSL and Sigma Healthcare differed by 2.10 percentage points.
Impairments and restructuring in CSL’s FY26 accounts
CSL reported group revenue of USD 15.8 billion for the year to 30 June 2026, down 1% on a constant-currency basis. Underlying net profit after tax and before IP amortisation was USD 3.1 billion, down 2% in constant currency. The company recorded a statutory loss after tax of USD 2.6 billion following restructuring costs and asset impairments. Operating Cash Flow was USD 3.5 billion, down 1%.
Pre-tax impairments reached USD 7.1 billion, with USD 5.5 billion recognised in the second half. CSL cited changes in commercial expectations, generic competition timelines, regulatory developments and assumptions about site use among the principal factors. One-off pre-tax restructuring costs were USD 799 million. CSL reported around USD 176 million in savings by year-end under its transformation program, which included combining commercial and medical-affairs functions across Behring and Vifor. CSL maintained a total FY26 Dividend of USD 2.92 per share, including a final dividend of USD 1.62. The company had completed an AUD 1 billion buyback during FY26 and announced a further AUD 1.1 billion program.
Plasma sales and the FY27 segment outlook
CSL Behring recorded revenue of USD 11.4 billion, down 1% in constant currency. Immunoglobulin sales were flat at USD 6.2 billion on that basis. The company cited adjustments to US channel inventory, changes to Medicare Part D and prior-year tender losses. Albumin sales decreased 17% in constant currency to USD 1.1 billion, following government cost-containment measures in China. HEMGENIX sales increased 25% on the same currency basis.
CSL expected Behring revenue to rise by a mid-single-digit rate in FY27, with immunoglobulin sales growing at a mid-to-high single-digit rate. It expected low-single-digit growth at Seqirus and an approximately 25% decline at Vifor. For Vifor, it cited competition from generic iron products, the end of the relevant US transitional add-on drug payment period for VELPHORO and revocation of the Marketing authorisation for TAVNEOS. Seqirus revenue declined 8% in constant currency to USD 2.0 billion. The company attributed the decline to the prior period’s avian influenza outbreak revenue, which did not recur. Global seasonal influenza sales rose 4% in constant currency.
CSL’s FY27 group outlook
CSL’s shares fell over the five days by less than the index. The annual release recorded a statutory loss after impairments and restructuring, alongside an FY27 forecast for broadly flat group revenue and approximately 5% underlying net profit growth at FY26 exchange rates.



_11_20_2026_20_27_34_097200.jpg)


Please wait processing your request...